ReviewMedical oncology (Northwood, London, England)2025
The dual role of PCDH9 in tumors, neurological and developmental diseases.
Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Tourette syndrome.Nature reviews. Disease primers · 2026Review
- Epithelial-Mesenchymal Transition Markers in Clear Cell Renal Cell Carcinoma: Expression Patterns and Prognostic Significance.Journal of personalized medicine · 2026Article
- Association of APOBEC mutagenesis with stromal and endothelial niche remodeling and PCDH9-linked signaling alterations in colorectal cancer.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Protocadherin 9 (PCDH9), a member of the δ1-protocadherin family, plays a crucial role in regulating cell polarity, tumor suppression, and neurodevelopment. This is achieved through its dual functions of extracellular calcium-dependent adhesion and intracellular signal transduction. In the context of tumors, PCDH9 inhibits epithelial-mesenchymal transition and cell cycle progression in various cancer types, such as liver cancer and glioma, via the GSK-3β/Snail1 axis. However, in Group 4 medulloblastoma, functionally acquired mutations in PCDH9 drive cancer development through the non-classical Wnt pathway. The expression of PCDH9 is tightly regulated by microRNAs (e.g., miR-589-3p) and epigenetic silencing mechanisms. Within the nervous system, PCDH9 deficiency gives rise to abnormal autistic behaviors, disruptions in hippocampal migration, and abnormal cerebrospinal fluid circulation. Its potential for clinical translation is evident in several areas, including the use of methylation as a prognostic marker, β-eucalyptol-mediated therapy to restore PCDH9, and strategies that target the piRNA-PI3K/AKT axis. Looking ahead, it is essential to conduct in-depth analyses of its evolutionary adaptability and formulate strategies targeting the adherent-signal interface.
Indexed as
Identifiers
40986169What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.